ASCT2 Inhibitor

Lc-BPE is the highest affinity novel chemical tool for characterizing the role of Alanine-Serine-Cysteine Transporter 2 (ASCT2), a sodium-dependent transporter in a variety of tissues, in cancer and other diseases from this study.

Contributors

Inventor	Institute
Christof Grewer	Binghamton University

Cat. #:	160702
Tool sub type:	Inhibitor
Research Fields:	Genetics
Application:	molecular docking, electrophysiology, transport assays in proteoliposomes and cryo-EM structure determination of ASCT2
Purpose:	Inhibitor

Alternate name:	L-cis hydroxyproline biphenyl ester (Lc-BPE)
Selectivity:	Stereoselective

Primary target:	NA

Shipping conditions:	Dry Ice

References:	doi: https://doi.org/10.1101/2020.05.29.124305

Unfortunately this tool is not currently available through our online checkout process. Please contact our team directly to obtain further information on accessing this tool.

Enquire about this Tool

If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Request a license

Get support

New to CancerTools?

We are a trusted, non-profit platform for cancer research products, part of Cancer Research UK – by sourcing your cancer research tools from us you help fund future cancer research.

Find out more

Related Tools for Small molecules

Cat. #

Tool Name

151831

Protein Kinase D inhibitor CRT0066101 Small Molecule (Tool Compound)

Key Info

Cat. #:	151831
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing
Application:	In Panc-1 subcutaneous xenograft model, orally administration of CRT0066101 at the dosage of 80 mg/kg/d for 24 days significantly suppressed pancreatic cancer growth. Moreover, when CRT0066101 reached its peak concentration (12 Îźmol/L) in tumor model, the expression of activated PKD1/2 in the treated tumor explants was substantially decreased. It was concluded that CRT0066101 given orally at 80 mg/kg/d for 21 days in Panc-1 orthotropic model suppressed tumor growth potently in vivo. Clinical…

View Tool

151832

LIMK inhibitor CRT0105950 Small Molecule (Tool Compound)

Key Info

Cat. #:	151832
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing
Application:	The compounds exhibit low uM potency in breast cancer cells showing dose dependent inhibition of phosphorylation of the LIMK substrate cofilin. Treatment of MDA-MB-231 breast cancer cells with the compounds significantly reduces their ability to invade a matrigel plug in an inverse in vitro invasion assay. Furthermore, the inhibitors effectively reduce fibroblast-led collective invasion in a co-culture organotypic model.

View Tool

151879

AKR1C3 inhibitor CRT0083914 Small Molecule (Tool Compound)

Key Info

Cat. #:	151879
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing

View Tool

152709

Dual DNA-PK/PI3K inhibitor KU-0060648 Small Molecule (Tool Compound)

Key Info

Cat. #:	152709
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing
Application:	KU-0060648 enhances the anti-tumour activity of etoposide in both MCF7 and SW620 xenograft models, and has single-agent activity in the MCF7 xenograft model. KU-0060648 exhibits differential effects on growth inhibition, but is not profoundly cytotoxic in a panel of human cancer cell lines. It inhibits DNA-PK and PI-3K with greater potency in MCF7 than SW620 cell using cell-based assays. Five-day exposure to 1 mM KU-0060648 inhibits cell proliferation by more than 95% in MCF7 cells but only b…

View Tool

152754

CDK2 inhibitor NU6301 Small Molecule (Tool Compound)

Key Info

Cat. #:	152754
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing
Application:	The prodrug NU6301 rapidly generated NU6102 in vitro in mouse plasma, and tumour NU6102 levels in vivo consistent with activity in vitro. Eight or 12 hourly dosing of 120 mg/kg NU6301 for 10 days was well tolerated in SKUT-1B tumour-bearing mice and inhibited Rb phosphorylation in tumour tissue. Two (8 hourly dosing) and 3 (12 hourly dosing) day tumour growth delay was observed (p=0.04 and p=0.007, respectively) following NU6301 administration. NU6102 selectively inhibited the growth of CDK2 WT (wild type) versus KO MEFs (knockout mouse embryo fibroblasts) (GIââ (concentration required to inhibit cell growth by 50%) 14 ÎźM versus >30 ÎźM), and was more growth-inhibitory in p53 mutant or null versus p53 WT cells (p=0.02), and in Rb (retinoblastoma protein) WT SKUT-1B versus SKUT 1 Rb deficient cells (p=0.01). In SKUT-1B cells NU6102 induced a G2 arrest, inhibition of Rb phosphorylation and cytotoxicity (LCââ 2.6 ÎźM for a 24h exposure).

View Tool

By Category

By Cancer Type

More

ASCT2 Inhibitor

Contributors

Related Tools for Small molecules

Tool enquiry